Elevated levels of apoptosis regulator proteins p53 and bcl-2 are independent prognostic biomarkers in surgically treated clinically localized prostate cancer

Journal of Urology

Volumn 156, Issue 4, 1996, Pages 1511-1516

  Bauer, John J ^b   Sesterhenn, Isabell A ^b   Mostofi, F K ^b   Mcleod, David G ^b   Srivastava, Shiv ^b   Moul, Judd W ^a  

^a UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^b NONE

Author keywords

genes; immunohistochemistry; p53; prostatectomy; prostatic neoplasms

Indexed keywords

BIOLOGICAL MARKER; FORMALDEHYDE; MONOCLONAL ANTIBODY; PARAFFIN; PROSTATE SPECIFIC ANTIGEN; PROTEIN BCL 2; PROTEIN P53;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER RECURRENCE; CONTROLLED STUDY; DIAGNOSIS; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY; PROTO ONCOGENE; SURVIVAL RATE; TREATMENT FAILURE; TUMOR SUPPRESSOR GENE;

EID: 0029795396     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(01)65641-6     Document Type: Article

References (35)

1. Boring, C. C., Squires, T. S. and Tong, T.: Cancer statistics 1994. CA Cancer J. Clin., 44: 7, 1994.
2. Lu-Yao, G. L., McLerran, D., Wasson, J. and Wennberg, J. E.: An assessment of radical prostatectomy: time trends, geographic variation and outcomes. J.A.M.A., 269: 2633, 1993.
3. Hockenbury, D., Nuñez, G., Milliman, C., Schreiber, R. D. and Korsmeyer, S. J.: Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature, 348: 334, 1990.
4. Bissonnette, R. P., Echeverri, F., Mahboubi, A. and Green, D. R.: Apoptotic cell death induced by c-myc is inhibited by bcl-2. Nature, 359: 552, 1992.
5. Korsmeyer, S. J.: Bcl-2 initiates a new category of oncogenes: regulators of cell death. Blood, 80: 879, 1992.
6. Lane, D. P.: p53, guardian of the genome. Nature, 358: 15, 1992.
7. Oren, M.: The involvement of oncogenes and tumor suppressor genes in the control of apoptosis. Cancer Metastasis Rev., 11: 141, 1992.
8. Chiou, S., Rao, L. and White, E.: bcl-2 blocks p53-dependent apoptosis. Mol. Cell Biol., 14: 2556, 1994.
9. Miyashita, T., Harigai, M., Hanada, M. and Reed, J. C.: Identification of a p53-dependent negative response element in the bcl-2 gene. Cancer Res., 54: 3131, 1994.
10. Haldar, S., Negrini, M., Mamo, M., Sabbioni, S. and Croce, C. M.: Down-regulation of bcl-2 by p53 in breast cancer cells. Cancer Res., 54: 2095, 1994.
11. Marin, M. C., Hsu, B., Meyn, R. E., Donehower, L. A., El-Naggar, A. K. and McDonnell, T. J.: Evidence that p53 and bcl-2 are regulators of a common cell death pathway important for in vivo lymphomagenesis. Oncogene, 9: 3107, 1994.
12. Martikainen, P., Kyprianou, N., Tucker, R. W. and Isaacs, J. T.: Programmed death of nonproliferating androgen-independent prostate cancer cells. Cancer Res., 51: 4693, 1991.
13. Colombel, M., Olsson, C. A., Ng, P. Y. and Buttyan, R.: Hormone-regulated apoptosis results from reentry of differentiated prostate cells onto a defective cell cycle. Cancer Res., 52: 4313, 1992.
14. McDonnell, T. J., Truncoso, P., Brisbay, S. M., Logothetis, C., Chung, L. W., Hsieh, J. T., Tu, S. M. and Campbell, M. L.: Expression of the proto-oncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res., 52: 6940, 1992.
15. Colombel, M., Symmans, F., Gil, S., O'Toole, K. M., Chopin, D., Benson, M., Olsson, C. A., Vorsmeyer, S. and Buttyan, R.: Detection of the apoptosis-suppressing onco-protein bcl-2 in hormone refractory human prostate cancers. Am. J. Pathol., 143: 390, 1993.
16. Brandstrom, A., Westin, P., Bergh, A., Cajander, S. and Damber, J. E.: Castration induces apoptosis in the ventral prostate but not in an androgen-sensitive prostatic adenocarcinoma in the rat. Cancer Res., 54: 3594, 1994.
17. Landstrom, M., Damber, J. E. and Bergh, A.: Prostatic tumor regrowth after initially successful castration therapy may be related to a decreased apoptotic cell death rate. Cancer Res., 54: 4281, 1994.
18. Kallakury, B. V. S., Figgie, J., Leihovich, B., Rifkin, M., Kaufman, R., Figgie, H. L., Nazeer, T. and Ross, J. S.: Increased bcl-2 protein levels in prostatic adenocarcinomas are not associated with rearrangements in the 2.8 kb major break-point region or with p53 protein accumulation. Mod. Pathol., abstract 447, 8: 78A, 1995.
19. Wertz, I. E., Edwards, R., Deitch, A. D., Gumerlock, P. H. and deVere White, R. W.: Apoptotic blocks in prostate cancer therapy. J. Urol., abstract 968, 1995.
20. Perlman, H., Zhang, X., Raffo, A. and Buttyan, R.: Increased bax/bcl-2 ratio correlates with the onset of apoptosis in the castrated rat ventral prostate gland. J. Urol., abstract 866, 153: 445A, 1995.
21. Aprikian, I., Robinson, M., Fuller, C., Boyds, J., Neal, D. E. and Hamdy, F. C.: bcl-2 protein combined with p53 mutant expression correlates with hormone refractory disease and poor prognosis in human prostatic adenocarcinoma. J. Urol., abstract 217, 153: 283A, 1995.
22. Galli, S., Gaboardi, F., Rozzola, A. and Ferrari, A.: Immunohistochemical expression of bcl-2, p53, KI-67 and chromograms in prostatic carcinoma. Correlation with stage and grade. J. Urol., abstract 1018, 153: 483A, 1995.
23. Thomas, D. J., Robinson, M., King, P., Hason, T., Charlton, R., Martin, J., Carr, M. and Neal, D. E.: p53 expression and clinical outcomes in prostate cancer. Br. J. Urol., 72: 778, 1993.
24. Shurbaji, S. M., Kalbfleisch, J. H. and Thurmond, T. S.: Immunohistochemical detection of p53 protein as a prognostic indicator in prostate cancer. Human Pathol., 26: 106, 1995.
25. Bauer, J. J., Sesterhenn, I. A., Mostofi, K. F., McLeod, D. G., Srivastava, S. and Moul, J. W.: p53 nuclear protein expression is an independent prognostic marker in clinically localized prostate cancer patients undergoing radical prostatectomy. Clin. Cancer Res., vol. 1, pp. 1295-1300, 1995.
26. Partin, A. W. and Oesterling, J. E.: The clinical usefulness of prostatic-specific antigen: update. J. Urol., 152: 1358, 1994.
27. Gleason, D. F.: Histological grading and clinical staging of prostate carcinoma. In: Urologic Pathology: The Prostate. Edited by M. Tannenbaum. Philadelphia: Lea and Febiger, pp. 171-197, 1977.
28. Mostofi, F. K., Sesterhenn, I. A. and Sobin, L. H.: Histological Typing of Prostate Tumors. Geneva: World Health Organization, 1980.
29. Obovi, M., Wheeler, T. M. and Scardino, P. T.: The American Joint Committee on Cancer and International Union Against Cancer. TNM classification of prostate cancer. Cancer, 73:104, 1994.
30. Heidenberg, H. B., Sesterhenn, I. A., Gaddipati, P., Weghorst, C. M., Buzard, G. S., Moul, J. W. and Srivastava, S.: Alterations of the tumor suppressor gene p53 in a high fraction of treatment resistant prostate cancer. J. Urol., 154: 414, 1995.
31. Kaplan, E. L. and Meier, P.: Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc., 53: 457, 1958.
32. Cox, D. R.: Regression models and life-tables (with discussion). J. R. Stat. Soc. Ser. B., 34: 187, 1972.
33. Piris, M. A., Pezzella, F., Martinez-Montero, J. C., Orradre, J. L., Villuendas, R., Sanchez-Beato, M., Cuena, R., Cruz, M. A., Martinez, B., Garrido, M. C., Gatter, K., Aiello, A., Delia, D., Giardini, R. and Rilke, F.: p53 and bcl-2 expression in high grade B-cell lymphomas: correlation with survival time. Br. J. Cancer, 69: 337, 1994.
34. Silverstrini, R., Verneroni, S., Daidone, M. G., Bernie, E., Borabi, P., Mezzetti, M., DiFronzo, G., Rilke, F. and Veronesi, U.: The bcl-2 protein: a prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients. J. Natl. Cancer Inst., 16: 449, 1994.
35. Berges, R. R., Furuya, Y., Remington, L., English, H. F., Jacks, T., and Isaacs, J. T.: Cell proliferation, DNA repair, and p53 function are not required for programmed cell death of prostatic glandular cells induced by androgen ablation. Proc. Natl. Acad. Sci., 90: 8910, 1993.